Clinical Trials

50 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07508761 2026-04-02

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

52 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07500831 2026-03-30

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

Phase NA Not yet recruiting

43 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07493980 2026-03-27

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07480733 2026-03-25

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Phase 1/2 Not yet recruiting

480 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

52 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 1/2 Not yet recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

24 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07410234 2026-02-13

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

110 enrolled

Breast

Breast Neoplasms

NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

440 enrolled

Gynecologic

Cervical Cancer Metastatic

NCT06952621 2026-01-30

TD-NEOE3V3

390 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT07371897 2026-01-28

SHINE

154 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07363330 2026-01-26

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

32 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT07362186 2026-01-23

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

400 enrolled

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled